TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

AUREGEN BIOTHERAPEUTICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

AUREGEN BIOTHERAPEUTICS

ST13

US500000079214833

Class

5, 9, 40, 42, 44

Filing

79214833

Registration

5521659

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

36

Latest update

04/17/2026

Classification

Registered

Trademark type

Word

Nice classes

5, 9, 40, 42, 44

Filing date

04/13/2017

Registration date

07/24/2018

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

02/07/2025

Last transaction

04/17/2026

Responsible office

United States Patent and Trademark Office

Status code

709

Official register

Principal Register

Drawing code

4

Owner type

33

Owner location

CH

Examiner

MAIHOS, JESSIE ANDREA

Law office

N30

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Auregen BioTherapeutics SA

Representatives

Gary D. Krugman Sughrue Mion, PLLC

Technical classification

Nice Classes

Class 5Class 9Class 40Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Biological implants, namely, a vital processed human or animal connective tissue; biological tissue for implantation; cells for medical use; human tissue for allografts; living cells for medical use; implants comprised of living tissue for guided tissue regeneration; implants comprising living tissue; implantable materials comprised of living tissue for use in guided tissue regeneration; skin grafts; surgical implants composed of living tissue; vascular grafts being living tissue; biological molecules to assist with the development of tissue, namely, peptides, polypeptides, nucleosides, amino acids; natural biomaterials for bone and tissue augmentation for medical use; natural biomaterials for bone filling for medical purposes; natural biomaterials for filling cartilage for medical purposes; surgical implants comprising living tissues; biological tissue cultures for medical purposes, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Class 9

Laboratory apparatus for the manufacture of living tissue and three-dimensional organs, namely, incubators and cell culture apparatus for laboratory use for the manufacture of living tissue and three dimensional organs; laboratory apparatus specially adapted for scientific research performed in laboratories for the manufacture of living tissue and three dimensional organs; bioreactors for cell culture; print heads for ink-jet printers; laboratory equipment for scientific use and research, namely, systems comprising a liquid distributor, an imaging facility being medical imaging equipment, related control software, and related analysis software, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Class 40

3D printing services; 3D printing services, namely, customized creation of three-dimensional parts using rapid prototyping equipment; 3D biological printing services; biological 3D printing services

Class 42

Technical research in the field of biomaterials, 3D bioprinting and tissue engineering; three-dimensional biological printing research; tissue engineering research; scientific and medical research and development in the field of bioprinting; research and development of 3D processes and technology; scientific services relating to the isolation and cultivation of human tissues and cells, excluding services used for a diagnosis; scientific and medical research and development in the field of the manufacture of tissue; development and culture of artificial tissue and cells in the nature of tissue engineering; tissue engineering services; industrial analysis and research services in the field of tissue engineering, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Class 44

Medical services in the field of cellular immunotherapy and transplant, excluding services used for a diagnosis; human cell and tissue bank services; medical services regarding the collection and preservation of cells for medical use, all of the aforementioned for in vivo use in the fields of therapeutic and aesthetic treatment

Publications

History of USPTO decisions and trademark events.

36 publications found

INNT

TOTAL INVALIDATION PROCESSED BY THE IB

04/16/2026

INTS

TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

03/30/2026

INPC

INVALIDATION PROCESSED

03/30/2026

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

10/07/2025

C71T

CANCELLED SECTION 71

02/07/2025

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

07/24/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/14/2019

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/14/2019

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

11/23/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

11/06/2018

FIMP

FINAL DISPOSITION PROCESSED

11/06/2018

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/24/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

07/24/2018

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

06/19/2018

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

06/15/2018

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/08/2018

PUBO

PUBLISHED FOR OPPOSITION

05/08/2018

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/18/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/30/2018

LIMN

LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED

03/23/2018

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/16/2018

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/16/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/14/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/14/2018

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/14/2018

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

12/22/2017

RFNT

REFUSAL PROCESSED BY IB

10/07/2017

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

09/16/2017

RFRR

REFUSAL PROCESSED BY MPU

09/16/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/13/2017

CNRT

NON-FINAL ACTION WRITTEN

09/12/2017

MAFR

APPLICATION FILING RECEIPT MAILED

09/05/2017

DOCK

ASSIGNED TO EXAMINER

08/31/2017

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/31/2017

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

08/25/2017

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

08/24/2017

Continuous trademark protection

Get notified about every new filing that threatens AUREGEN BIOTHERAPEUTICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.